FrancophonIA/ELRC3.0 huggingface dataset:
English: • The active substance is apalutamide.
Maltese: • Is-sustanza attiva hija apalutamide.
English: Ethnicity and race
Maltese: Etniċità u razza
English: Pharmacotherapeutic group: Endocrine therapy, anti-androgens, ATC code: L02BB05
Maltese: Terapija endokrinarja, antiandroġeni, Kodiċi ATC: L02BB05
English: Бизнес Парк София, сграда 4 София 1766
Maltese: Бизнес Парк София, сграда 4
English: Iron oxide black (E172) Iron oxide yellow (E172) Macrogol
Maltese: Iron oxide iswed (E172) Iron oxide isfar (E172) Macrogol
English: Colloidal anhydrous silica Croscarmellose sodium Hypromellose acetate succinate Magnesium stearate Microcrystalline cellulose Microcrystalline cellulose (silicified)
Maltese: Colloidal anhydrous silica Croscarmellose sodium Hypromellose acetate succinate Magnesium stearate Microcrystalline cellulose Microcrystalline cellulose (silikifikat)
English: Polyvinyl alcohol (partially hydrolysed) Talc
Maltese: Polyvinyl alcohol (parzjalment idrolizzat)
English: Erleada contains sodium
Maltese: Erleada fih sodium
English: Τηλ: +357 22 207 700
Maltese: Λευκωσία Τηλ: +357 22 207 700
English: (e.g. omeprazole)
Maltese: (eż. omeprazole)
English: Figure 1: Kaplan-Meier metastasis-free survival (MFS) curve in Study ARN-509-003
Maltese: Kaplan-Meier ta' sopravivenza mingħajr metastastasi (MFS, metastasis-free survival) fl-Istudju ARN-509-003
English: Nervous system disorders uncommon: seizure (see section 4.4)
Maltese: Disturbi fis-sistema nervuża mhux komuni: aċċessjoni (ara sezzjoni 4.4)
English: No in vitro inhibition of organic anion transporter 1 (OAT1) was observed.
Maltese: Ma ġiet osservata l-ebda inibizzjoni tat-trasportatur 1 talanjoni organiċi (OAT1, organic anion transporter 1).
English: Table 1: Adverse reactions identified in clinical studies
Maltese: Tabella 1: Reazzjonijiet avversi identifikati fi studji kliniċi
English: • treat heart rhythm problems (e.g. quinidine, disopyramide, amiodarone, sotalol, dofetilide,
Maltese: • jitrattaw problemi bir-ritmu tal-qalb (eż. quinidine, disopyramide, amiodarone, sotalol,
English: The racial distribution was 66% Caucasian, 5.6% Black, 12% Asian, and 0.2% Other.
Maltese: Id-distribuzzjoni tar-razza kienet 66% Kawkasi, 5.6% Suwed, 12% Asjatiċi, u 0.2% Oħrajn.
English: Endocrine disorders common: hypothyroidism*
Maltese: Disturbi fis-sistema endokrinarja komuni: ipotirojdiżmu*
English: The film-coating contains iron oxide black (E172), iron oxide yellow (E172), macrogol, polyvinyl alcohol (partially hydrolysed), talc, and titanium dioxide (E171).
Maltese: Il-kisja b'rita fiha iron oxide iswed (E172), iron oxide isfar (E172), macrogol, polyvinyl alcohol (parzjalment idrolizzat), talc, u titanium dioxide (E171).
English: INFORMATION IN BRAILLE Erleada 60 mg
Maltese: Erleada 60 mg
English: Janssen Cilag SpA Via C. Janssen Borgo San Michele Latina 04100, Italy
Maltese: Janssen Borgo San Michele Latina 04100, L-Italja
English: Subjects treated with Erleada and ADT showed significant improvement over those treated with ADT alone for the following secondary endpoints of time to metastasis (HR = 0.28; 95% CI: 0.23, 0.34; p < 0.0001), progression-free survival (PFS) (HR = 0.30; 95% CI: 0.25, 0.36; p < 0.0001); time to symptomatic progression (HR = 0.45; 95% CI: 0.32, 0.63; p < 0.0001); and a trend for overall survival (OS) (HR = 0.70; 95% CI: 0.47 1.04; p = 0.0742).
Maltese: Individwi ttrattati b'Erleada u ADT urew titjib sinifikanti fuq dawk ttrattati b'ADT waħdu għalliskopijiet sekondarji finali li ġejjin ta' żmien għall-metastasi (HR = 0.28; 95% CI: 0.23, 0.34; p < 0.0001), sopravivenza mingħajr progressjoni (PFS, progression-free survival) (HR = 0.30; 95% CI: 0.25, 0.36; p < 0.0001); żmien għall-progressjoni bis-sintomi (HR = 0.45; 95% CI: 0.32, 0.63; p < 0.0001) (ara Figura 3); u t-tendenza ta' sopravivenza totali (OS, overall survival) (HR = 0.70; 95% CI: 0.47 1.04; p = 0.
English: Do not take Erleada if:
Maltese: Tiħux Erleada jekk:
English: • lower cholesterol levels (e.g. ‘statins' such as rosuvastatin, simvastatin)
Maltese: • ibaxxu l-livelli tal-kolesterol (eż. ‘statins' bħal rosuvastatin, simvastatin)
English: • treat anxiety (e.g. midazolam, diazepam)
Maltese: • jittrattaw l-ansjetà (eż. midazolam, diazepam)
English: • treat epilepsy (e.g. phenytoin, valproic acid)
Maltese: • jitrattaw l-epilessija (eż. phenytoin, valproic acid)
English: There is also a risk of increased formation of active metabolites.
Maltese: Hemm ukoll riskju ta' żieda fil-formazzjoni ta' metaboliti attivi.
English: • treat HIV infection (e.g. ritonavir, efavirenz, darunavir)
Maltese: • jitrattaw infezzjoni bl-HIV (eż. ritonavir, efavirenz, darunavir)
English: In vitro studies showed that apalutamide and N-desmethyl apalutamide are moderate to strong CYP3A4 and CYP2B6 inducers, are moderate inhibitors of CYP2B6 and CYP2C8, and weak inhibitors of CYP2C9, CYP2C19, and CYP3A4.
Maltese: Studji in vitro urew li apalutamide u N-desmethyl apalutamide huma indutturi moderati sa qawwija ta' CYP3A4 u CYP2B6, huma inibituri moderati ta' CYP2B6 u CYP2C8, u inibituri dgħajfa ta' CYP2C9, CYP2C19, u CYP3A4.
English: In Study ARN-509-003, fracture was reported for 11.7% of patients treated with Erleada and 6.5% of patients treated with placebo.
Maltese: Fl-Istudju ARN-509-003, ġie rrappurtat ksur fi 11.7% tal-pazjenti ttrattati b'Erleada u 6.5% talpazjenti ttrattati bi plaċebo.
English: It is metabolised primarily by CYP2C8 and CYP3A4 to form N-desmethyl apalutamide.
Maltese: Huwa jiġi metabolizzat primarjament minn CYP2C8 u CYP3A4 biex jifforma N-desmethyl apalutamide.
English: The most common adverse reactions are fatigue (30%), skin rash (24% of any grade and 5% Grade 3 or 4), weight decreased (16%), arthralgia (16%), and fall (16%).
Maltese: L-aktar reazzjonijiet avversi komuni huma għeja (30%), raxx fil-ġilda (24% ta' kwalunkwe grad u 5% ta' Grad 3 jew 4), tnaqqis fil-piż (16%), artralġja (16%), u waqgħa (16%).
English: Metabolism and nutrition disorders common: hypercholesterolaemia common: hypertriglyceridaemia
Maltese: Disturbi fil-metaboliżmu u n-nutrizzjoni komuni: iperkolesterolemija komuni: ipertrigliċeridemija
English: A major metabolite, N-desmethyl apalutamide, exhibited one-third the in vitro activity of apalutamide.
Maltese: Metabolit prinċipali, N-desmethyl apalutamide, wera terz tal-attività ta' apalutamide in vitro.
English: • The other ingredients of the tablet core are colloidal anhydrous silica, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and silicified microcrystalline cellulose.
Maltese: • Is-sustanzi l-oħra tal-qalba tal-pillola huma colloidal anhydrous silica, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, u microcrystalline cellulose silikifikat.
English: Based on in vitro data, inhibition of organic cation transporter 2 (OCT2), organic anion transporter 3 (OAT3) and multidrug and toxin extrusions (MATEs) by apalutamide and its N-desmethyl metabolite cannot be excluded.
Maltese: Abbażi ta' data in vitro, inibizzjoni tat-trasportatur 2 tal-katjoni organiċi (OCT2, organic cation transporter 2), tat-trasportatur 3 tal-anjoni organiċi (OAT3, organic anion transporter 3) u tat-tfigħ 'il barra ta' ħafna mediċini u tossini (MATE, multidrug and toxin extrusions) b'apalutamide u l-metabolit tiegħu N-desmethyl ma jistgħux jiġu esklużi.
English: Frequency categories are defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000) and not known (frequency cannot be estimated from the available data).
Maltese: Il-kategoriji ta' frekwenza huma ddefiniti kif ġej: komuni ħafna (≥ 1/10); komuni (≥ 1/100 sa < 1/10); mhux komuni (≥ 1/1,000 sa < 1/100); rari (≥ 1/10,000 sa < 1/1,000); rari ħafna (< 1/10,000) u mhux magħruf (ma tistax tittieħed stima tal-frekwenza mid-data disponibbli).
English: Induction of CYP3A4 by apalutamide suggests that UDP-glucuronosyl transferase (UGT) may also be induced via activation of the nuclear pregnane X receptor (PXR).
Maltese: Induzzjoni ta' CYP3A4 b'apalutamide tissuġġerixxi li tista' ssir ukoll induzzjoni ta' UDP-glucuronosyl transferase (UGT) permezz ta' attivazzjoni tar-riċettur nukleari pregnane X (PXR, nuclear pregnane X receptor).
English: Apalutamide was shown to be a weak inducer of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptide 1B1 (OATP1B1) clinically.
Maltese: Apalutamide intwera li huwa induttur dgħajjef tal-glikoproteina P (P-gp, P-glycoprotein), tal-proteina ta' reżistenza tal-kanċer tas-sider (BCRP, breast cancer resistance protein), u tal-polypeptide 1B1 li jittrasporta anjoni organiċi (OATP1B1, organic anion transporting polypeptide 1B1) b'mod kliniku.
English: The median age was 74 years (range 48-97) and 26% of subjects were 80 years of age or older.
Maltese: Il-medjan tal-età kien 74 sena (firxa 48-97) u 26% tal-individwi kellhom 80 sena jew aktar.
English: Seizure occurred in 0.2% of patients receiving Erleada in clinical studies.
Maltese: Aċċessjoni seħħet f'0.2% tal-pazjenti li kienu qed jirċievu Erleada fi provi kliniċi.
English: • treat bacterial infections (e.g. moxifloxacin, clarithromycin)
Maltese: • jitrattaw infezzjonijiet bil-batterji (eż. moxifloxacin, clarithromycin)
English: Medicinal products that induce CYP3A4 or CYP2C8
Maltese: Prodotti mediċinali li jinduċu CYP3A4 jew CYP2C8
English: Apalutamide and N-desmethyl apalutamide are 96% and 95% bound to plasma proteins, respectively, and mainly bind to serum albumin with no concentration dependency.
Maltese: Apalutamide u N-desmethyl apalutamide huma 96% u 95% marbuta mal-proteina tal-plażma, rispettivament, u jintrabtu l-aktar mal-albumina fis-serum mingħajr dipendenza fuq il-konċentrazzjoni.
English: You may have an increased risk of side effects.
Maltese: Jista' jkollok riskju akbar ta' effetti sekondarji.
English: Medicinal products which prolong the QT interval Since androgen deprivation treatment may prolong the QT interval, the concomitant use of Erleada with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g., quinidine, disopyramide) or class III (e.g., amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics (e.g. haloperidol), etc. should be carefully evaluated (see section 4.4).
Maltese: Minħabba li t-trattament ta' deprivazzjoni tal-androġeen jista' jtawwal l-intervall QT, l-użu ta' Erleada flimkien ma' prodotti mediċinali magħrufa li jtawlu l-intervall QT jew ma' prodotti mediċinali li jistgħu jinduċu Torsade de pointes bħal prodotti mediċinali antiarritmiċi tal-klassi IA (eż., quinidine, disopyramide) jew tal-klassi III (eż., amiodarone, sotalol, dofetilide, ibutilide), methadone, moxifloxacin, antipsikotiċi, (eż. haloperidol), eċċ. għandhom jiġu evalwati b'attenzjoni (ara sezzjoni 4.4).
English: Clinical and pharmacokinetic data are not available for patients with severe hepatic impairment (Child-Pugh Class C).
Maltese: Data klinika u farmakokinetika mhijiex disponibbli għall-pazjenti b'indeboliment sever tal-fwied (Klassi C ta' Child-Pugh).
English: At steady-state, the mean (CV%) Cmax and AUC values for the major active metabolite, N-desmethyl apalutamide, were 5.9 µg/mL (18%) and 124 µg.h/mL (19%), respectively.
Maltese: Fl-istat fiss, il-valuri tal-medja (CV%) tas-Cmax u tal-AUC għall-metabolit prinċipali attiv, N-desmethyl apalutamide, kienu 5.9 µg/mL (18%) u 124 µg.siegħa/mL (19%), rispettivament.
English: Mean (CV%) AUC metabolite/parent drug ratio for N-desmethyl apalutamide following repeat-dose administration was about 1.3 (21%).
Maltese: Il-medja (CV%) tal-AUC tal-proporzjon tal-metabolit/tas-sustanza oriġinali għal N-desmethyl apalutamide wara għoti ta' dożi ripetuti kienet madwar 1.3 (21%).
English: PL-02-135 Warszawa Tel.:+48 22 237 60 00
Maltese: Warszawa Tel.:+48 22 237 60 00
English: In a drug-drug interaction study using a cocktail approach, co-administration of Erleada with single oral doses of sensitive CYP substrates resulted in a 92% decrease in the AUC of midazolam (CYP3A4 substrate), 85% decrease in the AUC of omeprazole (CYP2C19 substrate), and 46% decrease in the AUC of S-warfarin (CYP2C9 substrate).
Maltese: Fi studju dwar interazzjoni bejn mediċina u oħra bl-użu tal-approċ ‘cocktail', l-għoti flimkien ta' Erleada ma' dożi waħdiet ta' sustrati sensittivi għal CYP wassal għal tnaqqis ta' 92% fl-AUC ta' midazolam (sustrat ta' CYP3A4), tnaqqis ta' 85% fl-AUC ta' omeprazole (sustrat ta' CYP2C19), u tnaqqis ta' 46% fl-AUC tal-warfarin S (sustrat ta' CYP2C9).
English: 10 people).
Maltese: 0 ms).
English: Apalutamide was negative for genotoxicity in a standard battery of in vitro and in vivo tests.
Maltese: Apalutamide kien negattiv għal tossicità fil-ġeni f'sensiela ta' testijiet in vitro u in vivo standard.
English: Cardiac disorders not known: QT prolongation (see sections 4.4 and 4.5)
Maltese: Disturbi fil-qalb mhux magħruf: l-intervall QT mtawwal (ara sezzjonijiet 4.4 u 4.5)
English: • treat gout (e.g. colchicine)
Maltese: • jitrattaw il-gotta (eż. colchicine)
English: Population pharmacokinetic analyses showed that age (range: 18 to 94 years) does not have a clinically meaningful influence on the pharmacokinetics of apalutamide.
Maltese: Analiżi ta' famakokinetika ta' popolazzjoni urew li l-età (firxa : 18 sa 94 sena) m'għandhiex influwenza ta' sinifikat kliniku fuq il-farmakokinetika ta' apalutamide.
English: Falls were reported for 15.6% of patients treated with Erleada versus 9.0% of patients treated with placebo (see section 4.4).
Maltese: 6% tal-pazjenti ttrattati b'Erleada versus 9.0% tal-pazjenti ttrattati bi plaċebo (ara sezzjoni 4.4).
English: This medicine contains less than 1 mmol sodium (23 mg) per 240 mg dose (4 tablets), that is to say essentially ‘sodium-free'.
Maltese: Din il-mediċina fiha inqas minn 1 mmol ta' sodium (23 mg) f'kull doża ta' 240 mg (4 pilloli), li tista' tgħid hija ‘mingħajr sodium'.
English: Metabolism is the main route of elimination of apalutamide.
Maltese: Il-metaboliżmu huwa r-rotta prinċipali ta' eliminazzjoni ta' apalutamide.
English: Concomitant use of Erleada with medicinal products that are primarily metabolised by CYP3A4 (e.g., darunavir, felodipine, midazolam, simvastatin), CYP2C19 (e.g., diazepam, omeprazole), or CYP2C9 (e.g., warfarin, phenytoin) can result in lower exposure to these medicinal products.
Maltese: L-użu ta' Erleada flimkien ma' prodotti mediċinali li huma metabolizzati primarjament minn CYP3A4 (eż., darunavir, felodipine, midazolam, simvastatin), CYP2C19 (eż., diazepam, omeprazole), jew CYP2C9 (eż., warfarin, phenytoin) jista' jwassal għal esponiment aktar baxx għal dawn il-prodotti mediċinali.
English: For the most common adverse reactions, see section 4.8.
Maltese: Għall-aktar reazzjonijiet avversi komuni, ara sezzjoni 4.8.
English: A total of 1207 subjects with NM-CRPC were randomised 2:1 to receive either apalutamide orally at a dose of 240 mg once daily in combination with androgen deprivation therapy (ADT) (medical castration or prior surgical castration) or placebo with ADT in a multicenter, double-blind, clinical study (Study ARN-509-003).
Maltese: Total ta' 1,207 individwi b'NM-CRPC intagħżlu b'mod arbitrarju 2:1 biex jew jirċievu apalutamide mill-ħalq bid-doża ta' 240 mg darba kuljum flimkien ma' terapija ta' deprivazzjoni tal-androġen (ADT, androgen deprivation therapy) (kastrazzjoni medika jew kastrazzjoni kirurġika qabel) jew plaċebo flimkien ma' ADT fi studju kliniku b'ħafna ċentri, fejn la l-investigaturi u lanqas l-individwi ma kienu jafu liema sustanza qed tintuża (Studju ARN-509-003).
English: A drug-drug interaction study using a cocktail approach showed that co-administration of Erleada with single oral doses of sensitive transporter substrates resulted in a 30% decrease in the AUC of fexofenadine (P-gp substrate) and 41% decrease in the AUC of rosuvastatin (BCRP/OATP1B1 substrate) but had no impact on Cmax.
Maltese: Studju ta' interazzjoni bejn mediċina u oħra bl-użu tal-approċ ‘cocktail', wera li l-għoti ta' Erleada flimkien ma' dożi waħdiet ta' sustrati ta' trasportaturi sensittivi wassal għal tnaqqis ta' 30% fl-AUC ta' fexofenadine (sustrat ta' P-gp) u tnaqqis ta' 41% fl-AUC ta' rosuvastatin (sustrat ta' BCRP/OATP1B1) iżda ma kellu l-ebda impatt fuq is-Cmax.
English: A dedicated hepatic impairment study compared the systemic exposure of apalutamide and N- desmethyl apalutamide in subjects with baseline mild hepatic impairment (N=8, Child-Pugh Class A, mean score = 5.3) or moderate hepatic impairment (N=8, Child-Pugh Class B, mean score = 7.6)
Maltese: Studju ddedikat għal indeboliment tal-fwied qabbel l-esponiment sistemiku ta' apalutamide u N- desmethyl apalutamide f'individwi li fil-linja bażi kellhom indeboliment ħafif tal-fwied (N=8, Klassi A ta' Child-Pugh, punteġġ medju = 5.3) jew indeboliment moderat tal-fwied (N=8, Klassi B ta' Child-Pugh, punteġġ medju = 7.6) versus kontrolli f'saħħithom b'funzjoni normali tal-fwied (N=8).
English: 30-day carton
Maltese: Kartuna ta' 30 jum
English: Erleada works by blocking the activity of hormones called androgens (such as testosterone).
Maltese: Erleada jaħdem billi jimblokka l-attività ta' ormoni msejħa androġeni (bħal ma huwa t-testosterone).
English: In vitro data indicate that apalutamide and its N-desmethyl metabolite are not substrates for BCRP, OATP1B1 or OATP1B3.
Maltese: Data in vitro tindika li apalutamide u l-metabolit tiegħu N-desmethyl mhumiex sustrati għal BCRP, OATP1B1 jew OATP1B3.
English: Following a single oral administration of radiolabeled apalutamide, 89% of the radioactivity was recovered up to 70 days post-dose: 65% was recovered in urine (1.2% of dose as unchanged apalutamide and 2.7% as N-desmethyl apalutamide) and 24% was recovered in feces (1.5% of dose as unchanged apalutamide and 2% as N-desmethyl apalutamide).
Maltese: Wara għoti ta' darba mill-ħalq ta' apalutamide radjutikkettat, 89% tar-radjuattività ġiet irkuprata sa 70 jum wara d-doża: 65% ġiet irkuprata fl-awrina (1.2% tal-doża bħala apalutamide mhux mibdul u 2.7% bħala N-desmethyl apalutamide) u 24% ġie rkuprat mill-ippurgar (1.5% tad-doża bħala apalutamide mhux mibdul u 2% bħala N-desmethyl apalutamide).
English: In the apalutamide arm 64 (7.9%) subjects developed symptomatic progression compared with 63 (16%) in the placebo arm, with a hazard ratio of 0.447 (95% CI: 0.315, 0.634), which met the pre-specified O'Brien Fleming type efficacy boundary for significance, p < 0.00008.
Maltese: Fil-fergħa ta' apalutamide 64 (7.9%) individwu żviluppaw progressjoni bis-sintomi meta mqabbla ma' 63 (16%) fil-fergħa tal-plaċebo, bi proporzjon ta' periklu ta' 0.447 (95% CI: 0.315, 0.634), li ssodisfa l-konfini ta' effikaċa għal sinifikanza tat-tip O'Brien Fleming ta' p < 0.00008, speċifikata minn qabel.
English: Each bottle contains 120 tablets and a total of 6 g of desiccant.
Maltese: Kull flixkun fih 120 pillola u total ta' 6 g ta' desikkant.
English: Apalutamide and N-desmethyl apalutamide are further metabolised to form the inactive carboxylic acid metabolite by carboxylesterase.
Maltese: Apalutamide u N-desmethyl apalutamide jiġu metabolizzati aktar biex jiffurmaw il-metabolit mhux attiv carboxylic acid permezz ta' carboxylesterase.
English: • treat hayfever and allergies (e.g. fexofenadine)
Maltese: • jittrattaw hayfever u allerġiji (eż. fexofenadine)
English: At steady-state, mean (CV%) Cmax and AUC values for apalutamide were 6 µg/mL (28%) and 100 µg.h/mL (32%), respectively.
Maltese: Fl-istat fiss, il-medja (CV%) tas-Cmax u l-valuri tal-AUC għal apalutamide kieu 6 µg/mL (28%) u100 µg.siegħa/mL (32%), rispettivament.
English: The contribution of CYP2C8 and CYP3A4 in the metabolism of apalutamide is estimated to be 58% and 13% following single dose but the level of contribution is expected to change at steady-state due to induction of CYP3A4 by apalutamide after repeat dose.
Maltese: Il-kontribuzzjoni ta' CYP2C8 u CYP3A4 fil-metaboliżmu ta' apalutamide hija stmata li hija 58% u 13% wara doża waħda iżda fl-istat fiss il-livell ta' kontribuzzjoni huwa mistenni li jinbidel minħabba induzzjoni ta' CYP3A4 permezz ta' apalutamide wara dożi ripetuti.
English: If Erleada is co-administered with an anticoagulant metabolised by CYP2C9 (such as warfarin or acenocoumarol), additional International Normalised Ratio (INR) monitoring should be conducted (see section 4.5).
Maltese: Jekk Erleada jingħata flimkien ma' antikoagulant metabolizzat minn CYP2C9 (bħal ma huwa warfarin jew acenocoumarol), għandu jsir monitoraġġ addizzjonali tal-Proporzjon Normalizzat Internazzjonali (INR, International Normalised Ratio) (ara sezzjoni 4.5).
English: Medicinal products that inhibit CYP2C8
Maltese: Prodotti mediċinali li jinibixxu CYP2C8
English: • treat fungal infections (e.g. itraconazole, ketoconazole)
Maltese: • jitrattaw infezzjonijiet bil-fungi (eż. itraconazole, ketoconazole)
English: PHARMACEUTICAL FORM AND CONTENTS 120 tablets
Maltese: 120 pillola
English: • treat cancer (e.g. lapatinib, methotrexate)
Maltese: • jitrattaw il-kanċer (eż. lapatinib, methotrexate)
English: See below.
Maltese: Tista'
English: ibutilide)
Maltese: dofetilide, ibutilide)
English: Based on population pharmacokinetic analysis, there were no clinically relevant differences in apalutamide pharmacokinetics between White (Caucasian or Hispanic or Latino; N=761), Black (of African heritage or African American; N=71), Asian (non-Japanese; N=58) and Japanese (N=58).
Maltese: Suwed (ta' dixxendenza Afrikana jew Amerikani Afrikani; N=71), Asjatiċi (mhux Ġappuniżi; N=58) u Ġappuniżi (N=58).
English: Grade 3 skin rashes (defined as covering > 30% body surface area [BSA]) were reported with Erleada treatment in 5.2% of patients.
Maltese: Raxx ta' Grad 3 fil-ġilda (ddefinit bħala wieħed li jiksi > 30% tal-erja tas-superfiċje tal-ġisem [BSA, body surface area]) ġie rrappurtat bi trattament b'Erleada f'5.2% tal-pazjenti.
English: 28-day carton
Maltese: Kartuna ta' 28 jum
English: • treat thyroid conditions (e.g. levothyroxine)
Maltese: • jittrattaw kondizzjonjiet tat-tirojde (eż. levothyroxine)
English: Other medicines and Erleada
Maltese: Mediċini oħra u Erleada
English: The effects of CYP3A4 or CYP2C8 inducers on the pharmacokinetics of apalutamide have not been evaluated in vivo.
Maltese: L-effetti ta' indutturi ta' CYP3A4 jew CYP2C8 fuq il-farmakokinetika ta' apalutamide ma ġewx evalwati in vivo.
English: Drug transporters
Maltese: Trasportaturi tal-mediċini
English: Following a single oral 240 mg dose of apalutamide, the geometric mean ratio (GMR) for AUC and Cmax for apalutamide in subjects with mild impairment was 95% and 102%, respectively, and the GMR for AUC and Cmax of apalutamide in subjects with moderate impairment was 113% and 104%, respectively, compared to healthy control subjects.
Maltese: Wara doża waħda ta' 240 mg ta' apalutamide mill-ħalq, il-proporzjon ġeometriku medju (GMR, geometric mean ratio) għall-AUC u s-Cmax ta' apalutamide f'individwi b'indeboliment ħafif kien 95% u 102%, rispettivament, u l-GMR għall-AUC u s-Cmax ta' apalutamide f'individwi b'indeboliment moderat kien 113% u 104%, rispettivament, meta mqabbel ma' individwi f'saħħithom bħala kontroll.
English: Skin rash included rash, rash maculo-papular, rash generalised, urticaria, rash pruritic, rash macular, conjunctivitis, erythema multiforme, rash papular, skin exfoliation, genital rash, rash erythematous, stomatitis, drug eruption, mouth ulceration, rash pustular, blister, papule, pemphigoid, skin erosion, and rash vesicular.
Maltese: Ir-raxx fil-ġilda kien jinkludi raxx, raxx makulopapulari, raxx mifrux, urtikarja, raxx bil-ħakk, raxx makulari, konġuntivite, eritema multiforme, raxx papulari, ġilda taqa' qxur qxur, raxx fil-ġenitali, raxx eritematuż, stomatite, reazzjoni fil-ġilda minħabba l-mediċina, ulċerazzjoni fil-ħalq, raxx bl-imsiemer, nuffata, ponta, pemfigojd, tagħwir fil-ġilda, u raxx vesikulari.